Download PDF
Semin Neurol 2011; 31(2): 158-168
DOI: 10.1055/s-0031-1277988
© Thieme Medical Publishers

Immune-Mediated Encephalopathies with an Emphasis on Paraneoplastic Encephalopathies

Amy A. Pruitt1
  • 1Department of Neurology, University of Pennsylvania, Philadelphia Pennsylvania
Further Information

Publication History

Publication Date:
17 May 2011 (online)

    Permissions and Reprints

Corrected by:

Immune-Mediated Encephalopathies with an Emphasis on Paraneoplastic EncephalopathiesSemin Neurol 2011; 31(03): 356-356
DOI: 10.1055/s-0031-1291959

ABSTRACT

Recent identification of syndromes encompassing psychiatric symptoms, seizures, and movement disorders has led to effective treatments for several previously obscure conditions now known to be immune-mediated encephalopathies. In contrast to long-recognized paraneoplastic neurologic syndromes associated with antibodies to intracellular antigens, these more recently described disorders are not always paraneoplastic, are associated with cell surface antibodies, and may respond to immunosuppressive therapies. In this review, the author discusses clinical presentations, differential diagnosis, immunologic evaluation, and therapeutic options for both groups of disorders.

KEYWORDS

Paraneoplastic syndromes - limbic encephalitis - NMDAR encephalitis - voltage-gated potassium channel antibodies

REFERENCES

  • 1 Rosenfeld M R, Dalmau J. Update on paraneoplastic and autoimmune disorders of the central nervous system.  Semin Neurol. 2010;  30 (3) 320-331
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Antoine J C, Camdessanché J P. Peripheral nervous system involvement in patients with cancer.  Lancet Neurol. 2007;  6 (1) 75-86
    CrossrefPubMedGoogle Scholar
  • 3 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the peripheral nerves.  Curr Opin Neurol. 2005;  18 (5) 598-603
    CrossrefPubMedGoogle Scholar
  • 4 Flanagan E P, McKeon A, Lennon V A et al.. Autoimmune dementia: clinical course and predictors of immunotherapy response.  Mayo Clin Proc. 2010;  85 (10) 881-897
    CrossrefPubMedGoogle Scholar
  • 5 Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies.  Neurologist. 2007;  13 (3) 140-147
    CrossrefPubMedGoogle Scholar
  • 6 Vincent A, Irani S R, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins.  Curr Opin Neurol. 2010;  23 (2) 144-150
    CrossrefPubMedGoogle Scholar
  • 7 Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS.  J Neurol. 2010;  257 (4) 509-517
    CrossrefPubMedGoogle Scholar
  • 8 Dalmau J, Rosenfeld M R. Paraneoplastic syndromes of the CNS.  Lancet Neurol. 2008;  7 (4) 327-340
    CrossrefPubMedGoogle Scholar
  • 9 Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. PNS Euronetwork . Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.  Arch Neurol. 2010;  67 (3) 330-335
    CrossrefPubMedGoogle Scholar
  • 10 Tüzün E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment.  Neurologist. 2007;  13 (5) 261-271
    CrossrefPubMedGoogle Scholar
  • 11 Josephs K A, Ahlskog J E, Parisi J E et al.. Rapidly progressive neurodegenerative dementias.  Arch Neurol. 2009;  66 (2) 201-207
    CrossrefPubMedGoogle Scholar
  • 12 Geschwind M D, Shu H, Haman A, Sejvar J J, Miller B L. Rapidly progressive dementia.  Ann Neurol. 2008;  64 (1) 97-108
    CrossrefPubMedGoogle Scholar
  • 13 Graus F, Saiz A, Lai M et al.. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations.  Neurology. 2008;  71 (12) 930-936
    CrossrefPubMedGoogle Scholar
  • 14 McKeon A, Ahlskog J E, Britton J A, Lennon V A, Pittock S J. Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images.  Arch Neurol. 2009;  66 (2) 268-271
    CrossrefPubMedGoogle Scholar
  • 15 Dalmau J, Graus F, Villarejo A et al.. Clinical analysis of anti-Ma2-associated encephalitis.  Brain. 2004;  127 (Pt 8) 1831-1844
    CrossrefPubMedGoogle Scholar
  • 16 Castle J, Sakonju A, Dalmau J, Newman-Toker D E. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease.  Nat Clin Pract Neurol. 2006;  2 (10) 566-572, quiz 573
    CrossrefPubMedGoogle Scholar
  • 17 Saiz A, Bruna J, Stourac P et al.. Anti-Hu-associated brainstem encephalitis.  J Neurol Neurosurg Psychiatry. 2009;  80 (4) 404-407
    CrossrefPubMedGoogle Scholar
  • 18 Pittock S J, Debruyne J, Krecke K N et al.. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS).  Brain. 2010;  133 (9) 2626-2634
    CrossrefPubMedGoogle Scholar
  • 19 Heinrich A, Vogelgesang S, Kirsch M, Khaw A V. Intravascular lymphomatosis presenting as rapidly progressive dementia.  Eur Neurol. 2005;  54 (1) 55-58
    CrossrefPubMedGoogle Scholar
  • 20 Sips G J, Amory C F, Delman B N, Kleinman G M, Lipsey L R, Tuhrim S. Intravascular lymphomatosis of the brain in a patient with myelodysplastic syndrome.  Nat Rev Neurol. 2009;  5 (5) 288-292
    CrossrefPubMedGoogle Scholar
  • 21 Carney C P, Jones L, Woolson R F, Noyes Jr R, Doebbeling B N. Relationship between depression and pancreatic cancer in the general population.  Psychosom Med. 2003;  65 (5) 884-888
    CrossrefPubMedGoogle Scholar
  • 22 Turaga K K, Malafa M P, Jacobsen P B, Schell M J, Sarr M G. Suicide in patients with pancreatic cancer.  Cancer. 2011;  117 (3) 642-647
    CrossrefPubMedGoogle Scholar
  • 23 Silverman D H, Dy C J, Castellon S A et al.. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy.  Breast Cancer Res Treat. 2007;  103 (3) 303-311
    CrossrefPubMedGoogle Scholar
  • 24 Joshi G, Aluise C D, Cole M P et al.. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain.  Neuroscience. 2010;  166 (3) 796-807
    CrossrefPubMedGoogle Scholar
  • 25 Suzuki H I, Hangaishi A, Hosoya N et al.. Herpes simplex encephalitis and subsequent cytomegalovirus encephalitis after chemoradiotherapy for central nervous system lymphoma: a case report and literature review.  Int J Hematol. 2008;  87 (5) 538-541
    CrossrefPubMedGoogle Scholar
  • 26 Pruitt A A, Dalmau J, Detre J, Alavi A, Rosenfeld M R. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation.  Neurology. 2006;  67 (4) 676-678
    CrossrefPubMedGoogle Scholar
  • 27 Quan D, Hackney D B, Pruitt A A, Lenkinski R E, Cecil K M. Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS.  Neurology. 1999;  53 (1) 211-213
    CrossrefPubMedGoogle Scholar
  • 28 Seeley W W, Marty F M, Holmes T M et al.. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6.  Neurology. 2007;  69 (2) 156-165
    CrossrefPubMedGoogle Scholar
  • 29 Airas L, Päivärinta M, Röyttä M et al.. Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT.  Bone Marrow Transplant. 2010;  45 (3) 593-596
    CrossrefPubMedGoogle Scholar
  • 30 Weathers A L, Lewis S L. Rare and unusual ... or are they? Less commonly diagnosed encephalopathies associated with systemic disease.  Semin Neurol. 2009;  29 (2) 136-153
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Salvarani C, Brown Jr R D, Calamia K T et al.. Primary central nervous system vasculitis: analysis of 101 patients.  Ann Neurol. 2007;  62 (5) 442-451
    CrossrefPubMedGoogle Scholar
  • 32 Desestret V, Didelot A, Meyronet D, Bruyas A, Jouvet A, Honnorat J. Neurosarcoidosis with diencephalitis and anti-Ma2 antibodies.  Neurology. 2010;  74 (9) 772-774
    CrossrefPubMedGoogle Scholar
  • 33 Zandman-Goddard G, Chapman J K, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome.  Semin Arthritis Rheum. 2007;  36 (5) 297-315
    CrossrefPubMedGoogle Scholar
  • 34 Kimura A, Kanoh Y, Sakurai T et al.. Antibodies in patients with neuropsychiatric systemic lupus erythematosus.  Neurology. 2010;  74 (17) 1372-1379
    CrossrefPubMedGoogle Scholar
  • 35 Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren S I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors.  Eur J Neurol. 2005;  12 (5) 392-398
    CrossrefPubMedGoogle Scholar
  • 36 Kruer M C, Koch T K, Bourdette D N et al.. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica.  Neurology. 2010;  74 (18) 1473-1475
    CrossrefPubMedGoogle Scholar
  • 37 Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma.  Ann Neurol. 2005;  58 (4) 594-604
    CrossrefPubMedGoogle Scholar
  • 38 Dalmau J, Tüzün E, Wu H Y et al.. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma.  Ann Neurol. 2007;  61 (1) 25-36
    Google Scholar
  • 39 Sansing L H, Tüzün E, Ko M W, Baccon J, Lynch D R, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies.  Nat Clin Pract Neurol. 2007;  3 (5) 291-296
    CrossrefPubMedGoogle Scholar
  • 40 Hughes E G, Peng X, Gleichman A J et al.. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.  J Neurosci. 2010;  30 (17) 5866-5875
    CrossrefPubMedGoogle Scholar
  • 41 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld M R, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.  Lancet Neurol. 2011;  10 (1) 63-74
    Google Scholar
  • 42 Eker A, Saka E, Dalmau J et al.. Testicular teratoma and anti-N-methyl-d-aspartate receptor-associated encephalitis.  J Neurol Neurosurg Psychiatry. 2008;  79 (9) 1082-1083
    CrossrefPubMedGoogle Scholar
  • 43 Lebas A, Husson B, Didelot A, Honnorat J, Tardieu M. Expanding spectrum of encephalitis with NMDA receptor antibodies in young children.  J Child Neurol. 2010;  25 (6) 742-745
    CrossrefPubMedGoogle Scholar
  • 44 Zandi M S, Irani S R, Follows G, Moody A M, Molyneux P, Vincent A. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma.  Neurology. 2009;  73 (23) 2039-2040
    CrossrefPubMedGoogle Scholar
  • 45 Irani S R, Bera K, Waters P et al.. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.  Brain. 2010;  133 (Pt 6) 1655-1667
    CrossrefPubMedGoogle Scholar
  • 46 Florance N R, Davis R L, Lam C et al.. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents.  Ann Neurol. 2009;  66 (1) 11-18
    CrossrefPubMedGoogle Scholar
  • 47 Baltagi S A, Shoykhet M, Felmet K, Kochanek P M, Bell M J. Neurological sequelae of 2009 influenza A (H1N1) in children: a case series observed during a pandemic.  Pediatr Crit Care Med. 2010;  11 (2) 179-184
    CrossrefPubMedGoogle Scholar
  • 48 Ferioli S, Dalmau J, Kobet C A, Zhai Q J, Broderick J P, Espay A J. Anti-N-methyl-d-aspartate receptor encephalitis: characteristic behavioral and movement disorder.  Arch Neurol. 2010;  67 (2) 250-251
    PubMedGoogle Scholar
  • 49 Wong-Kisiel L C, Ji T, Renaud D L et al.. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis.  Neurology. 2010;  74 (19) 1550-1551
    CrossrefPubMedGoogle Scholar
  • 50 Labate A, Irani S R, Vincent A et al.. Anti-NMDA receptor encephalitis: a video case report.  Epileptic Disord. 2009;  11 (3) 267-269
    PubMedGoogle Scholar
  • 51 Dalmau J, Gleichman A J, Hughes E G et al.. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.  Lancet Neurol. 2008;  7 (12) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 52 González-Valcárcel J, Rosenfeld M R, Dalmau J. Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies.  Neurologia. 2010;  25 (7) 409-413
    PubMedGoogle Scholar
  • 53 Sébire G. In search of lost time from “demonic possession” to anti-N-methyl-d-aspartate receptor encephalitis.  Ann Neurol. 2010;  67 (1) 141-142, author reply 142–143
    PubMedGoogle Scholar
  • 54 Iizuka T, Sakai F, Ide T et al.. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.  Neurology. 2008;  70 (7) 504-511
    CrossrefPubMedGoogle Scholar
  • 55 Sabin T D, Jednacz J A, Staats P N. Case records of the Massachusetts General Hospital. Case 26-2008. A 26-year-old woman with headache and behavioral changes.  N Engl J Med. 2008;  359 (8) 842-853
    CrossrefPubMedGoogle Scholar
  • 56 Niehusmann P, Dalmau J, Rudlowski C et al.. Diagnostic value of N-methyl-d-aspartate receptor antibodies in women with new-onset epilepsy.  Arch Neurol. 2009;  66 (4) 458-464
    CrossrefPubMedGoogle Scholar
  • 57 Prüss H, Dalmau J, Harms L et al.. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin.  Neurology. 2010;  75 (19) 1735-1739
    CrossrefPubMedGoogle Scholar
  • 58 Dale R C, Irani S R, Brilot F et al.. N-methyl-d-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica.  Ann Neurol. 2009;  66 (5) 704-709
    CrossrefPubMedGoogle Scholar
  • 59 Gable M S, Gavali S, Radner A et al.. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis.  Eur J Clin Microbiol Infect Dis. 2009;  28 (12) 1421-1429
    CrossrefPubMedGoogle Scholar
  • 60 Bataller L, Galiano R, García-Escrig M et al.. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor.  Neurology. 2010;  74 (3) 265-267
    CrossrefPubMedGoogle Scholar
  • 61 Graus F, Boronat A, Xifró X et al.. The expanding clinical profile of anti-AMPA receptor encephalitis.  Neurology. 2010;  74 (10) 857-859
    CrossrefPubMedGoogle Scholar
  • 62 Lai M, Hughes E G, Peng X et al.. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location.  Ann Neurol. 2009;  65 (4) 424-434
    CrossrefPubMedGoogle Scholar
  • 63 Lancaster E, Lai M, Peng X et al.. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.  Lancet Neurol. 2010;  9 (1) 67-76
    CrossrefPubMedGoogle Scholar
  • 64 Hutchinson M, Waters P, McHugh J et al.. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody.  Neurology. 2008;  71 (16) 1291-1292
    CrossrefPubMedGoogle Scholar
  • 65 Clerinx K, Breban T, Schrooten M et al.. Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy.  Neurology. 2011;  76 (3) 303-304
    CrossrefPubMedGoogle Scholar
  • 66 Moscato E H, Jain A, Peng X, Hughes E G, Dalmau J, Balice-Gordon R J. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies.  Eur J Neurosci. 2010;  32 (2) 298-309
    CrossrefPubMedGoogle Scholar
  • 67 Belforte J E, Zsiros V, Sklar E R et al.. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes.  Nat Neurosci. 2010;  13 (1) 76-83
    CrossrefPubMedGoogle Scholar
  • 68 Vincent A, Buckley C, Schott J M et al.. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.  Brain. 2004;  127 (Pt 3) 701-712
    CrossrefPubMedGoogle Scholar
  • 69 Iranzo A, Graus F, Clover L et al.. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis.  Ann Neurol. 2006;  59 (1) 178-181
    CrossrefPubMedGoogle Scholar
  • 70 McKnight K, Jiang Y, Hart Y et al.. Serum antibodies in epilepsy and seizure-associated disorders.  Neurology. 2005;  65 (11) 1730-1736
    CrossrefPubMedGoogle Scholar
  • 71 Irani S R, Alexander S, Waters P et al.. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.  Brain. 2010;  133 (9) 2734-2748
    CrossrefPubMedGoogle Scholar
  • 72 Reid J M, Foley P, Willison H J. Voltage-gated potassium channel-associated limbic encephalitis in the West of Scotland: case reports and literature review.  Scott Med J. 2009;  54 (4) 27-31
    PubMedGoogle Scholar
  • 73 Geschwind M D, Tan K M, Lennon V A et al.. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease.  Arch Neurol. 2008;  65 (10) 1341-1346
    CrossrefPubMedGoogle Scholar
  • 74 Tan K M, Lennon V A, Klein C J, Boeve B F, Pittock S J. Clinical spectrum of voltage-gated potassium channel autoimmunity.  Neurology. 2008;  70 (20) 1883-1890
    CrossrefPubMedGoogle Scholar
  • 75 McKeon A, Marnane M, O'Connell M, Stack J P, Kelly P J, Lynch T. Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome.  Arch Neurol. 2007;  64 (10) 1528-1530
    CrossrefPubMedGoogle Scholar
  • 76 Fukata Y, Lovero K L, Iwanaga T et al.. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy.  Proc Natl Acad Sci U S A. 2010;  107 (8) 3799-3804
    CrossrefPubMedGoogle Scholar
  • 77 Lai M, Huijbers M GM, Lancaster E et al.. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.  Lancet Neurol. 2010;  9 (8) 776-785
    CrossrefPubMedGoogle Scholar
  • 78 Vincent A. Antibodies to contactin-associated protein 2 (CASPR2) in thymoma and Morvan's syndrome.  Ann Neurol. 2009;  66 (Suppl 13) S3
    CrossrefPubMedGoogle Scholar
  • 79 Saiz A, Blanco Y, Sabater L et al.. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.  Brain. 2008;  131 (Pt 10) 2553-2563
    CrossrefPubMedGoogle Scholar
  • 80 Malter M P, Helmstaedter C, Urbach H, Vincent A, Bien C G. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis.  Ann Neurol. 2010;  67 (4) 470-478
    CrossrefPubMedGoogle Scholar
  • 81 Psimaras D, Carpentier A F, Rossi C. PNS Euronetwork . Cerebrospinal fluid study in paraneoplastic syndromes.  J Neurol Neurosurg Psychiatry. 2010;  81 (1) 42-45
    CrossrefPubMedGoogle Scholar
  • 82 Bataller L, Wade D F, Graus F, Stacey H D, Rosenfeld M R, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.  Neurology. 2004;  62 (5) 778-782
    CrossrefPubMedGoogle Scholar
  • 83 Bernal F, Graus F, Pifarré A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis.  Acta Neuropathol. 2002;  103 (5) 509-515
    CrossrefPubMedGoogle Scholar
  • 84 Titulaer M J, Soffietti R, Dalmau J et al.. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.  Eur J Neurol. 2011;  18 (1) 19-e3
    CrossrefPubMedGoogle Scholar
  • 85 McKeon A, Apiwattanakul M, Lachance D H et al.. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review.  Arch Neurol. 2010;  67 (3) 322-329
    CrossrefPubMedGoogle Scholar
  • 86 Mathew R M, Vandenberghe R, Garcia-Merino A et al.. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis.  Neurology. 2007;  68 (12) 900-905
    CrossrefPubMedGoogle Scholar
  • 87 Erkmen C P, Fadul C E, Dalmau J, Erkmen K. Thymoma-associated paraneoplastic encephalitis (TAPE): diagnosis and treatment of a potentially fatal condition.  J Thorac Cardiovasc Surg. 2011;  141 (2) e17-e20
    CrossrefPubMedGoogle Scholar
  • 88 Rosenfeld M R, Dalmau J. Current therapies for paraneoplastic neurologic syndromes.  Curr Treat Options Neurol. 2003;  5 (1) 69-77
    CrossrefPubMedGoogle Scholar
  • 89 Lehmann H C, Hartung H P, Hetzel G R, Stüve O, Kieseier B C. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.  Arch Neurol. 2006;  63 (7) 930-935
    CrossrefPubMedGoogle Scholar
  • 90 Raju R, Rakocevic G, Chen Z et al.. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome.  Brain. 2006;  129 (Pt 12) 3270-3276
    CrossrefPubMedGoogle Scholar

Amy A PruittM.D. 

Department of Neurology, University of Pennsylvania

3400 Spruce Street, Philadelphia, PA 19104

Email: pruitt@mail.med.upenn.edu

      >